Chlamydia, a bacterial infection and one of the most common sexually transmitted diseases in the US, is illustrated here
Chlamydia, a bacterial infection and one of the most common sexually transmitted diseases in the US, is illustrated here

Chlamydia vaccine could become reality after successful clinical trial

STI is usually treated with antibiotics 

Sarah Young
Tuesday 13 August 2019 08:20
Comments

A vaccine to protect against chlamydia is now a step closer to becoming reality after a pioneering clinical trial has found the treatment to be safe.

Researchers from the Imperial College London and the Statens Serum Institut in Copenhagen tested two formulations of a vaccine, with each type given to 15 women aged between 19 and 45. Another five women were given a placebo.

All participants received three injections into their arm over four months, followed by two doses administered through a nasal spray in the weeks after.

Neither the women nor those monitoring the impact of the vaccine were aware of who was in which group.

Both formulations appeared to be safe, however researchers state that one stood out as a front runner and are now set to move this vaccine into the next phase of testing.

While further trials need to be carried out to determine whether it can fully protect against the infection, experts say it is an “important first step” in tackling the condition.

“The findings are encouraging as they show the vaccine is safe and produces the type of immune response that could potentially protect against chlamydia,” said Professor Robin Shattock, from Imperial College London.

“The next step is to take the vaccine forward to further trials, but until that's done, we won't know whether it is truly protective or not.”

According to the NHS, chlamydia is one of the most common sexually transmitted infections (STIs) in the UK.

It's passed on through unprotected sex and is particularly common in sexually active teenagers and young adults.

While chlamydia can normally be treated with a short course of antibiotics, the NHS states that it can be serious if it's not treated early on.

It can lead to infertility, as well as complications such as ectopic pregnancy, arthritis and increased susceptibility to other STIs such as HIV.

“The major issue with chlamydia is the long-term consequences,“ said Professor Shattock.

”It is very treatable if identified, but as many people don't have symptoms it can be missed, and the biggest problem is that it can go on to cause infertility in women.

“One of the problems we see with current efforts to treat chlamydia is that despite a very big screening, test and treat programme, people get repeatedly re-infected. If you could introduce a protective vaccine, you could break that cycle.”

The findings raise hopes that the vaccine could eventually be given at the same time as the HPV vaccine, which protects against certain cancers including that of the cervix.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in